Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 25, 2023Journal of the European Academy of Dermatology and VenereologyOpen Access

Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO ( ITALIAN LANDSCAPE PSORIASIS )

View Full Paper
Ask AI
Bookmark
Share

Authors

LGLuigi GargiuloHumanitas UniversityLILuciano IbbaHumanitas UniversityPMPiergiorgio MalagoliIRCCS Policlinico San Donato

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gargiulo et al. (2023) studied this question.

synapsesocial.com/papers/6ab62b26be29f64e08ad7008https://doi.org/10.1111/jdv.18913
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study2022 · 36 citations
  2. 2The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab2015 · 38 citations
  3. 3IL-23 inhibition for the treatment of psoriatic arthritis2021 · 19 citations
  4. 4Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study2022 · 58 citations
  5. 5What Can IBD Specialists Learn from IL-23 Trials in Dermatology?2022 · 25 citations